Looking to run with Big Pharma, a radiopharma startup with backing from Atlas, RA thinks it has the chops to compete
Amid a renaissance in the field of radiopharmaceuticals, a growing chorus of biopharma players is rushing the stage to capitalize on tech breakthroughs. Biotech blue-chippers RA Capital and Atlas Venture, sensing an opportunity, are now setting up their own startup to challenge the big boys.
Curie Therapeutics uncloaked from stealth Wednesday with $75 million in Series A funding from Atlas, RA and Access Biotechnology, with the goal of leveraging a seasoned team of experts to get the jump on the growing class of cancer therapeutics, the biotech said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
